# Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cumyl-pegaclone-schedule-i-designation/ > **Published:** 2026-06-22T14:59:37-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:38:37-04:00 > **Clinical Summary:** Explore the DEA's cumyl-pegaclone schedule i designation and its impact on synthetic cannabinoid regulation and clinical awareness. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis policyDEA scheduling[controlled substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/)Schedule I classificationfederal cannabis lawsynthetic cannabinoids regulationcannabis legislation reform Clinical Summary The U.S. Drug Enforcement Administration has placed cumyl-pegaclone, a synthetic cannabinoid analog, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, designating it as having high abuse potential with no accepted medical use. This regulatory action reflects ongoing efforts to control novel psychoactive substances that circumvent existing drug laws by chemically modifying known compounds like cannabinoids to evade legal restrictions. Cumyl-pegaclone and related synthetic cannabinoids pose significant [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) risks, producing more potent and unpredictable effects than natural cannabis, with reports of severe acute toxicity including psychosis, seizures, and cardiovascular complications. The scheduling decision underscores the challenge clinicians face in managing patients who use unregulated synthetic cannabinoid products obtained through illicit markets, which lack [quality control](https://cedclinic.com/alabama-medical-cannabis-commission-audit-violations/) and accurate labeling. Clinicians should remain alert to the potential for cumyl-pegaclone exposure in patients presenting with acute psychiatric, neurological, or cardiovascular symptoms and counsel patients that synthetic cannabinoids carry substantially greater harm than cannabis. Healthcare providers should counsel patients to avoid synthetic cannabinoid products entirely, as these Schedule I substances offer no therapeutic benefit and carry severe safety risks compared to regulated cannabis or approved cannabinoid medications. Clinical Perspective ⚕️ The Drug Enforcement Administration’s decision to place cumyl-pegaclone, a synthetic cannabinoid analog, in Schedule I reflects the ongoing challenge of regulating novel psychoactive substances that emerge faster than formal scheduling processes can address. While this regulatory action aims to prevent abuse of a compound with potential health risks similar to other synthetic cannabinoids, clinicians should recognize that scheduling decisions alone do not eliminate patient exposure or clinical encounters with these substances, as underground markets and chemical reformulation continue to fuel their availability. The lack of robust safety and pharmacology data for many novel synthetic cannabinoids complicates clinical risk stratification and [harm reduction](https://cedclinic.com/can-you-mix-weed-and-alcohol/) conversations with patients who may use these compounds as perceived alternatives to scheduled cannabis or opioids. Clinicians should remain vigilant for acute psychiatric symptoms, cardiac complications, and withdrawal syndromes associated with synthetic cannabinoid use, while acknowledging that treatment protocols remain largely empirical and that the evolving regulatory 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+CUMYL-PEGACLONE+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F13%2F2026-09566%2Fschedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F13%2F2026-09566%2Fschedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+CUMYL-PEGACLONE+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F13%2F2026-09566%2Fschedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Temporary Placement of 2-Fluorodeschloroketamine in Schedule I - [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-controlled-substance-scheduling-update/) - [Policy Watch: 20 Regulatory Updates — June 21, 2026](https://cedclinic.com/schedules-controlled-substances-placement-june-2026/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i](https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) Detailed coverage of the DEA’s decision to place cumyl-pegaclone in Schedule I, including regulatory context and clinical considerations. [Read More](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) Explore the temporary scheduling of 2-Fluorodeschloroketamine and its implications for synthetic drug regulation. [Explore](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) [Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) An overview of FDA-approved marijuana products rescheduling and the resulting changes in regulatory permit requirements. [Learn More](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).